

D1 61. (amended) The immunoconjugate of claim 60 wherein the therapeutic agent is a cytotoxin that is a ribosome binding toxin.

02 63. (amended) The immunoconjugate of claim 61 wherein the therapeutic agent is an exotoxin.

94. (new) The immunoconjugate of claim 59, wherein the antibody is a monoclonal antibody or a fragment of a monoclonal antibody.

95. (new) The immunoconjugate of claim 59, wherein the antibody is a Fab, F(ab')₂ or Fv fragment.

D3 96. (new) The immunoconjugate of claim 59, wherein the antibody is a bifunctional antibody with a binding specificity for two different antigens, one of the antigens being said Lewis Y cell membrane antigen of a carcinoma cell.

97. (new) The immunoconjugate of claim 59, wherein the antibody is a chimeric antibody.

98. (new) The immunoconjugate of claim 59, wherein the antibody is a humanized antibody.

99. (new) The immunoconjugate of claim 59, wherein the antibody is a human antibody.

100. (new) The immunoconjugate of claim 59, 94, 97, 98 or 99 which is purified.

Antibody 101. (new) An immunoconjugate that comprises an antibody joined to a therapeutic agent, wherein the antibody comprises an immunoglobulin or antigen-binding fragment thereof that competitively inhibits binding of the monoclonal antibody BR96, as

produced by the hybridoma deposited with the ATCC and assigned Accession No. HB10036, to a carcinoma cell.

102. (new) The immunoconjugate of claim 101, wherein the antibody is a monoclonal antibody or a fragment of a monoclonal antibody.

103. (new) The immunoconjugate of claim 101, wherein the antibody is a Fab, F(ab')₂ or Fv fragment.

104. (new) The immunoconjugate of claim 101, wherein the antibody is a bifunctional antibody with a binding specificity for two different antigens.

105. (new) The immunoconjugate of claim 101, wherein the antibody is a chimeric antibody.

106. (new) The immunoconjugate of claim 101, wherein the antibody is a humanized antibody.

107. (new) The immunoconjugate of claim 101, wherein the antibody is a human antibody.

108. (new) The immunoconjugate of claim 101, 102, 105, 106, or 107 which is purified.

109. (new) The immunoconjugate of claim 101 wherein the therapeutic agent is selected from the group consisting of a cytotoxin, an anti-tumor drug, a radioactive agent, a second antibody, and an enzyme.

110. (new) The immunoconjugate of claim 109, wherein the therapeutic agent is a cytotoxin that is a ribosome binding toxin.